Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Choroideremia (CHM) is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina.
Features include always present findings: Constriction of peripheral visual field, Nyctalopia, Pigmentary retinopathy, and Progressive visual loss and others; and common findings: Bone spicule pigmentation of the retina and Attenuation of retinal blood vessels. 14 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 5 | Retinal pigment epithelial mottling, Pigmentary retinopathy, Granular macular appearance |
Bones and joints | 1 | Bone spicule pigmentation of the retina |
Muscles | 1 | Chorioretinal atrophy |
Age of onset: middle age.
Affected males. Choroideremia (CHM) is characterized by progressive chorioretinal degeneration in affected males. Typically, symptoms evolve from night blindness to peripheral visual field loss, with central vision preserved until late in life. Males in their 40s have very good visual acuity but only a small visual field. In a large meta-analysis of more than 1,000 eyes, transition from a slow to more rapid decline in vision occurred at age 39 years . Later, around age 50-70 years, central vision becomes markedly impaired. Posterior subcapsular cataracts are similar to those observed in retinitis pigmentosa. Cystoid macular edema has been reported.
Source: GeneReviews — "Choroideremia"
CHM encodes CHM Rab escort protein (653 aa). Substrate-binding subunit of the Rab geranylgeranyltransferase (GGTase) complex. Highest expression in Cells Cultured fibroblasts (11.9 TPM) and Artery Tibial (10.3 TPM).
Choroideremia is caused by mutations in the CHM gene on chromosome X.
CHM is classified as a druggable target with score 0.0.
Genotype-phenotype correlations have not been demonstrated for this disorder.
Source: GeneReviews — "Choroideremia"
The diagnosis of choroideremia (CHM) should be suspected in males with the following clinical, electroretinogram (ERG), and visual field findings, and family history.
Clinical findings
Defective dark adaptation. Poor vision in the dark is commonly the first symptom in affected males, usually as a preteen.
Characteristic fundus appearance. Patchy areas of chorioretinal degeneration generally begin in the mid-periphery of the fundus. The areas of chorioretinal degeneration progress to marked loss of the retinal pigment epithelium and choriocapillaris (inner of the two vascular layers of the choroid that is composed largely of capillaries) with preservation of the deep choroidal vessels ( and ).
Source: GeneReviews — "Choroideremia"
Choroideremia (CHM) needs to be distinguished from the inherited retinal dystrophies summarized in . Table 2. Genes of Interest in the Differential Diagnosis of Choroideremia
Gene(s) | DiffDx Disorder | MOI | Clinical Characteristics of DiffDx Disorder |
|---|---|---|---|
Overlapping Features | Distinguishing Features ~80 genes1 | Nonsyndromic retinitis pigmentosa (RP) | ADARXL3 |
USH1G | Usher syndrome type 1 (USH1) |
Genetic testing for CHM is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for choroideremia has been reported in the published literature.
No approved treatments are currently available for choroideremia. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for choroideremia, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for choroideremia. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene | adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene | Biogen | 2014 | — | Designated |
No clinical practice guidelines for choroideremia have been published.
To establish the extent of disease and needs in an individual diagnosed with choroideremia (CHM), the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Ophthalmologic examination including best corrected visual acuity (BCVA), funduscopic examination, and visual field testing for a baseline
Spectral domain optical coherence tomography (SD-OCT) to evaluate and monitor the change of macular structure over time, especially ellipsoid zone (EZ), outer retinal tubulations, and chorioretinal atrophy. It is also helpful in identifying any comorbid maculopathy.
Referral to a low vision specialist or vision rehabilitation clinic may be particularly helpful as central vision declines and/or visual field becomes limited.
Consultation with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and implications of choroideremia in order to facilitate medical and personal decision making
Retinal detachment, which may occur more commonly in individuals with high myopia (as seen in CHM), is treated by conventional surgical techniques by an ophthalmologist. Cataract surgery may be required for individuals with a posterior subcapsular cataract.
Avoid the following:
UV exposure from sunlight reflected from water and snow
Smoking, a major risk factor for macular degeneration
Source: GeneReviews — "Choroideremia"
Gene replacement therapy using a subretinal delivery of AAV2-REP1 (Nightstar Therapeutics, UK) has been trialed in the UK, Canada, US, and Germany. Reports showed some gain in visual acuity in the treated eye compared to the untreated eye. However, some individuals experienced significant complications such as retinal overstretch and postoperative inflammation. This product is currently in a Phase III trial; results are expected in the coming years . Another gene augmentation agent that is being trialed uses an intravitreal delivery of 4D-110 (4D Molecular Therapeutics, USA) in individuals with genetically confirmed choroideremia (ClinicalTrials.gov). The trial is estimated to be completed in 2023. Search ClinicalTrials.
Source: GeneReviews — "Choroideremia"
8 trials found
Regular ophthalmologic examination to monitor progression of CHM is recommended, as affected individuals need advice regarding their levels of visual function. Kinetic visual field examinations provide practical information for both the clinician and the affected individual. SD-OCT imaging is a fundamental clinical tool to evaluate macular structure, especially when central vision is affected and cystoid macular edema is suspected.
Source: GeneReviews — "Choroideremia"
Phenotype severity distribution: 6 always present features, 2 common features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
8 clinical trials registered, 3 recruiting. Interventions under study include other interventions, gene therapy, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE3, 3 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06375239](https://clinicaltrials.gov/study/NCT06375239) | Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration | — | Ray Therapeutics, Inc. | RECRUITING |
[NCT06460844](https://clinicaltrials.gov/study/NCT06460844) | Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) | PHASE1 | Ray Therapeutics, Inc. | ACTIVE_NOT_RECRUITING |
[NCT02435940](https://clinicaltrials.gov/study/NCT02435940) | Inherited Retinal Degenerative Disease Registry | — | Foundation Fighting Blindness | RECRUITING |
[NCT05282953](https://clinicaltrials.gov/study/NCT05282953) | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) | PHASE1 | Kiora Pharmaceuticals, Inc. | UNKNOWN |
[NCT01866371](https://clinicaltrials.gov/study/NCT01866371) | High Resolution Retinal Imaging | — | University of Pennsylvania | RECRUITING |
70 publications have been identified in PubMed for choroideremia. Research spans Epidemiology / Natural History (23%), Basic Science / Preclinical (21%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 16 | 23% |
Laboratory research | 15 | 21% |
Research summaries | 13 | 19% |
Patient case studies | 10 | 14% |
Testing and diagnosis research | 6 | 9% |
Clinical study results | 4 |
Al-Moujahed A (2026). [PMID: 41891913](https://pubmed.ncbi.nlm.nih.gov/41891913/). *Ophthalmic Surg Lasers Imaging Retina*. [Epidemiology / Natural History]
Zhao AT (2026). [PMID: 41492572](https://pubmed.ncbi.nlm.nih.gov/41492572/). *Am J Ophthalmol Case Rep*. [Case Report / Case Series]
Han X (2026). [PMID: 42090280](https://pubmed.ncbi.nlm.nih.gov/42090280/). *Invest Ophthalmol Vis Sci*. [Diagnostic / Biomarker]
Zhao MJ (2026). [PMID: 42211215](https://pubmed.ncbi.nlm.nih.gov/42211215/). *Int J Ophthalmol*. [Other]
Dossett JP (2026). [PMID: 42183146](https://pubmed.ncbi.nlm.nih.gov/42183146/). *J Vitreoretin Dis*. [Case Report / Case Series]
Porter JJ (2026). [PMID: 41641696](https://pubmed.ncbi.nlm.nih.gov/41641696/). *Nucleic Acids Res*. [Gene Therapy / Novel Therapeutics]
Kritfuangfoo T (2026). [PMID: 41983914](https://pubmed.ncbi.nlm.nih.gov/41983914/). *Retina*. [Basic Science / Preclinical]
Golebka JP (2026). [PMID: 42227810](https://pubmed.ncbi.nlm.nih.gov/42227810/). *Transl Vis Sci Technol*. [Epidemiology / Natural History]
Niri F (2026). [PMID: 41714298](https://pubmed.ncbi.nlm.nih.gov/41714298/). *Am J Med Genet A*. [Basic Science / Preclinical]
Huang AM (2026). [PMID: 41906751](https://pubmed.ncbi.nlm.nih.gov/41906751/). *Curr Eye Res*. [Basic Science / Preclinical]
Data assembled from 10 of 12 sources · Last updated Sep 17, 2026, 9:16 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
RP develops in adolescence, progressively constricted visual fields impaired visual acuity. |
OAT | Gyrate atrophy of choroid retina (GACR) (OMIM 258870) | AR | The progressive nature of scalloped areas of chorioretinal atrophy in GACR may appear similar to findings in CHM. |
RPE65 | RP w/choroidal involvement (RP87) (OMIM 618697) | AD | Stellate, scalloped areas of chorioretinal atrophy, very similar to CHM |
Source: GeneReviews — "Choroideremia"
Other research | 3 | 4% |
New treatment approaches | 3 | 4% |
AI-curated news mentioning choroideremia
Updated Sep 16, 2026
A recent study highlights the role of somatic mosaicism and skewed X-chromosome inactivation in a female patient exhibiting a male-pattern choroideremia phenotype. This research could enhance understanding of the genetic mechanisms underlying choroideremia.